Related references
Note: Only part of the references are listed.Pharmacogenetics: implications for therapy in rheumatic diseases
Lesley Davila et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
Genetic and genomic predictors of anti-TNF response
Rita Prajapati et al.
PHARMACOGENOMICS (2011)
The soluble biomarker calprotectin (a S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab
Hilde Berner Hammer et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis
Tracey M. Farragher et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
Eli A. Stahl et al.
NATURE GENETICS (2010)
Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?
Jenny E. Higgs et al.
PHARMACOGENOMICS (2010)
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
C. Potter et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis
Peter C. Taylor et al.
NATURE REVIEWS RHEUMATOLOGY (2009)
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
Kimme L. Hyrich et al.
RHEUMATOLOGY (2009)
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
Fumihiko Takeuchi et al.
PLOS GENETICS (2009)
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Gregory M. Cooper et al.
BLOOD (2008)
Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2-*24)
Shuta Ujiie et al.
PHARMACOGENETICS AND GENOMICS (2008)
BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists
K. Chakravarty et al.
RHEUMATOLOGY (2008)
Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis
Hilde Berner Hammer et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Register
K. L. Hyrich et al.
RHEUMATOLOGY (2006)
Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years - Results from a large observational inception study
MAS Bukhari et al.
ARTHRITIS AND RHEUMATISM (2003)
Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-α antibody compared with methotrexate in long-standing rheumatoid arthritis
P Barrera et al.
RHEUMATOLOGY (2002)
Share Paper
